Dr. Reddy’s Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock’s future prospects, with ratings ranging from ‘Buy’ to ‘Sell’.
Largecaps showing no fundamental change despite market bounce: Nischal Maheshwari
Investors are closely watching sectors like banking, manufacturing, auto distribution, and aviation after a recent rate cut. Analysts see temporary margin pressure for banks and
December 8, 2025